Throughout the body, T cells monitor MHC-bound ligands expressed on the surface of
essentially all cell types. MHC ligands that trigger a T cell immune response are referred to …

Human leukocyte antigens (HLA) are cell-surface proteins that present peptides to T cells.
These peptides are bound within the peptide binding cleft of HLA, and together as a …

Comprehensive knowledge of the human leukocyte antigen (HLA) class-I and class-II
peptides presented to T-cells is crucial for designing innovative therapeutics against cancer …

Antigen presentation lies at the heart of immune recognition of infected or malignant cells.
For this reason, important efforts have been made to predict which peptides are more likely …

HLA-I molecules bind short peptides and present them for recognition by CD8+ T cells. The
length of HLA-I ligands typically ranges from 8 to 12 aa, but variability is observed across …

The development of immunological therapies that incorporate peptide antigens presented to
T cells by MHC proteins is a long sought-after goal, particularly for cancer, where mutated …

Identification of CD8+ T cell epitopes is critical for the development of immunotherapeutics.
Existing methods for major histocompatibility complex class I (MHC class I) ligand discovery …

The major histocompatibility complex (MHC) is a large genetic region with many genes,
including the highly polymorphic classical class I and II genes that play crucial roles in …

The magnitude of T cell responses to infection is a function of the naïve T cell repertoire
combined with the context and duration of antigen presentation. Using mass spectrometry …

The identification of T-cell epitopes is key for a complete molecular understanding of
immune recognition mechanisms in infectious diseases, autoimmunity and cancer. T-cell …